Pharmacy

Your Article Summary

See Latest Articles

Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
Sanofi-aventis, 09/14/09

Sanofi–aventis and Regeneron Pharmaceuticals, Inc. announced the discontinuation of the Phase 3 trial that evaluated aflibercept plus gemcitabine versus placebo plus gemcitabine for the first–line treatment of metastatic pancreatic cancer, based on the recommendations by an Independent Data Monitoring Committee. As part of a planned interim efficacy analysis, the IDMC determined that the addition of aflibercept to gemcitabine would be unable to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to placebo plus gemcitabine in this study.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09

Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09

 See all of Drug Trials

Today in Stomach/GI...keeping you current

Receive free subspecialty "5-minute updates" via email

Proton Pump Inhibitors and Pain
Pain Physician, 11/25/09

Clinical Features of Gastroduodenal Ulcer in Japanese Patients Taking Low-Dose Aspirin
Digestive Diseases and Sciences, 11/25/09

Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
Cephalon, 11/24/09

 See all of Stomach/GI